Tempero Bio has hit the brakes on a phase 2-stage alcohol use disorder (AUD) candidate while the biotech considers its ...
NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora’s M4 franchise; both programs have potential best-in-class pharmacology No convulsions observed in pre-clinical ...
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 29, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ...
Ivana Magovčević-Liebisch President and CEO, Dr Magovčević-Liebisch is an accomplished pharmaceutical and biotechnology ...
Neurocrine Biosciences has penned a deal with China’s TransThera Sciences potentially worth more than $880 million in ...
Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule ...
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 29, 2025 - Addex Therapeutics(SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing ...
Despite regulatory progress in many countries, skepticism and a lack of robust randomized trials continue to limit the use of medical cannabis in rheumatology.
The CALIBRATE study of encaleret for patients with ADH1 met all pre-specified primary and key secondary efficacy endpoints - ...
The latest update is out from Addex Therapeutics ( (CH:ADXN) ).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback